Berlin, 23 March 2020
Accelero Bioanalytics GmbH (“Accelero”) has received the authority permit for processing and analysis of SARS-CoV-2 in biological samples.
The Berlin State Office for Occupational Safety, Health Protection, and Technical Safety (LAGetSi) as well as the local Health Department in Treptow-Köpenick both allowed the processing and analysis of upper and lower respiratory specimen (swaps, sputum, bronchoalveolar lavage) via SARS-CoV-2 specific RT-PCR assays.
The company will also work on immunological assays for innate immune response monitoring like IgG and/or IgM detection and titer determination against SARS-CoV-2 in human serum.
Accelero can also provide FluoroSpot assays for direct and sensitive detection of IgG secreting cells in response to SARS-CoV-2 stimulation in vitro.
All services will be provided in full compliance to Good Laboratory Practice (GLP) regulations.
NOT FOR DIAGNOSTIC USE – FOR INFORMATION PURPOSES ONLY.
Please click hereto download the complete press release including a figure with SARS-CoV-2 RNA genomic organisation.
The figure shows the genomic organization of a SARS-CoV-2 RNA genome isolated and sequenced from a patient in a Japanese cruise ship (Severe acute respiratory syndrome coronavirus 2 SARS-CoV-2/Hu/DP/Kng/19-027 RNA, complete genome. Acc. No. LC528233, Hishiki T et al, 29-FEB-2020).
Accelero can provide three different assay formats:
(1) Three RT-PCR assays published by Institut Pasteur, Paris, FRANCE, targeting the genes RdRp IP2, RdRp IP4 and E, respectively.
(2) Three RT-PCR assays published by the CDC, Atlanta, UNITED STATES, targeting the nucleocapsid phosphoprotein.
(3) Three RT-PCR assays published by the Charité, Berlin, GERMANY, targeting the genes RdRp and E, respectively.
A sample is supposed to be positive for SARS-CoV-2 only if all three consecutive assays give a positive signal within the assay acceptance criteria.
Last update of this page: 12-MAY-2020 by CL